Magnolia Medical develops and manufactures innovative blood and bodily fluid collection devices that significantly improve the accuracy, consistency and predictability of critical in-vitro diagnostic (IVD) tests. False positive and false negative laboratory test results in the acute care setting create confusion and uncertainty that often lead to inappropriate, unnecessary treatments. These misdiagnoses often significantly increase utilization of antibiotics and associated complications as well as patient length of stay and risk for healthcare-associated infections (HAIs).
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
07/14/16 | $13,800,000 | Series B |
HealthQuest Capital | undisclosed |